Boundless Bio, Inc. (BOLD)
Last updated: 2026-10-22 04:30:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Boundless Bio, Inc. (BOLD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.43, with a market capitalization of $53.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.96 to $3.16. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$53.38M | |
$2.53 | |
$60.00 | |
$0.96 | |
$2.43 | |
60.76K | |
187.29K | |
-- | |
$3.16 | |
$0.96 | |
-- | |
-- |
Boundless Bio, Inc. (BOLD) Latest Closing Stock Price
Boundless Bio, Inc. (BOLD) last closed at $2.43 as of 2026-10-21 23:31:00, unchanged from the previous close of $2.43.
During the latest regular trading session, BOLD traded between $0.96 and $60.00, with a volume of 60.76K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Boundless Bio, Inc. (BOLD) 7-Day Stock Price Change
Over the past seven days, Boundless Bio, Inc. (BOLD) moved from $2.55 to $2.43, representing a decline of 4.63% ($0.12).
The stock traded between $2.28 and $2.69 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 265.15 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
BOLD 52-Week Price Position
Position in Range: 66.8%
BOLD is currently trading at $2.43, placing it 66.8% of the way from its 52-week low of $0.96 to its 52-week high of $3.16. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Boundless Bio, Inc. (BOLD)?
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Boundless Bio, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Boundless Bio, Inc. (BOLD) Stock on MEXC
Eligible investors can buy real shares of Boundless Bio, Inc. (BOLD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Boundless Bio, Inc. (BOLD) stock price today?
2.Is BOLD stock going up or down today?
3.What is BOLD pre-market price?
4.What is BOLD after-hours price?
5.Is BOLD stock trading now?
6.Where does BOLD sit relative to its 52-week high and low?
7.What sector is Boundless Bio, Inc. in?
8.What is Boundless Bio, Inc.'s market capitalization and where is it listed?
9.How is BOLD valued in terms of P/E ratio and EPS?
10.Does Boundless Bio, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
BOLD Stock Calculator
Estimate the value between BOLD shares and USD.
BOLD Shares to USD
1.00 BOLD shares = 2.432 USD
Calculations are estimates based on the latest available price and are for reference only.


